Skip to main content
Board of Directors
Innovation engine overview
Extracting microbial biodiversity
Screening for new activity
Active compound characterization
Technology platform overview
DEINOVE is pioneering the exploration of “microbial dark matter”
By revealing the metabolic potential of rare bacteria or still classified as uncultivable, the company tackles a global health and economic challenge:
DEINOVE announces a favorable opinion from the DSMB for the continuation of the Phase II clinical trial of DNV3837 in Clostridioides difficile infections
The DSMB* considered that the benefit/risk balance of antibiotic therapy with DNV3837 was in favor...
Issuance of 2nd tranche of €500,000 of notes convertibles into new shares
DEINOVE strengthens its cash position to finance its working capital needs and the pursuance of the...
More press releases